FGFR3 and neoplasm: When a highly antigenic tumor is entirely composed of cells harboring an activating FGFR3 mutation, anti-FGFR3 therapy may be necessary to minimize tumor burden as ICI shifts the balance in the tumor-CTL interactions towards tumor cell lysis and away from CTL exhaustion (Supplementary Figure 2.1).